The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis

American Journal of Respiratory and Critical Care Medicine

Volumn 151, Issue 6, 1995, Pages 1734-1739

  Donnelly, Arlene L ^b   Glass, Mitchell ^b   Minkwitz, Margaret C ^b   Casale, Thomas B ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE D4; LEUKOTRIENE D4 RECEPTOR; PLACEBO; ZAFIRLUKAST; TOLUENESULFONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEASONAL VARIATION; COMPARATIVE STUDY; DRUG ANTAGONISM; HAY FEVER; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE D4; MALE; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS; TOSYL COMPOUNDS;

EID: 0028990176     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.151.6.7767514     Document Type: Article

References (26)

1. Smith, J. M. 1988. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis (eczema). In E. Middleton, Jr., C. E. Reed, E. F. Ellis, N. F. Adkinson, Jr., and J. W. Yunginger, editors. Allergy: Principles and Practice. 3rd ed. Mosby Year Book, St. Louis. 891-929.
2. Togias, A., R. M. Naclerio, D. Proud, C. Baumgarten, S. Peters, P. S. Creticos, J. Warner, A. Kagey-Sobotka, N. F. Adkinson, Jr., and P. S. Norman. 1985. Mediator release during nasal provocation: a model to investigate the pathophysiology of rhinitis. Am. J. Med. 79:26-33.
3. Creticos, P. S., S. P. Peters, N. F. Adkinson, Jr., R. M. Naclerio, E. C. Hayes, P. S. Norman, and L. M. Lichtenstein. 1984. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N. Engl. J. Med. 310:1626-1630.
4. 4 in allergic rhinitis. Allergy 40:1-6.
5. 4. Br. J. Pharmacol. 80:497-502.
6. Marom, Z., J. H. Schelhamer, and M. Kaliner. 1981. Effect of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glyco-proteins from human airways in vitro. J. Clin. Invest. 67:1695-1702.
7. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin. Allergy 16:289-297.
8. 4 in allergic rhinitis. Ann. Allergy 60:537-540.
9. Lee, T. H., M. J. Walport, A. H. Wilkinson, M. Turner-Warwick, and A. B. Kay. 1981. Slow-reacting substance of anaphylaxis antagonist FPL55712 in chronic asthma. Lancet 2:304-305.
10. 4 antagonist L-649,923 on the response to inhaled antigen in asthma. J. Allergy Clin. Immunol. 79:811-816.
11. 4 receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am. Rev. Respir. Dis. 140:1336-1339.
12. Hay, D. W. P., R. M. Muccitelli, S. S. Tucker, L. M. Vickery-Clark, K. A. Wilson, J. G. Gleason, R. F. Hall, M. A. Wasserman, and T. J. Torphy. 1987. Pharmacologic profile of SKF 104353: a novel, potent and selective peptidoleukotirene receptor antagonist in guinea pig and human airways. J. Pharmacol. Exp. Ther. 243:474-481.
13. Welch, M., G. Feiss, H. Nelson, B. Paull, J. Smith, and R. Tobey. 1992. The effect of RD12525, a novel leukotriene antagonist, on the pulmonary function of asthmatics. J. Allergy Clin. Immunol. 89:236.
14. 4) receptor antagonist (MK-571) in patients with asthma. Am. Rev. Respir. Dis. 146:358-363.
15. Krell, R. D., D. Aharony, C. K. Buckner, R. A. Keith, E. J. Kusner, D. W. Snyder, P. R. Bernstein, V. G. Matassa, Y. K. Yee, F. J. Brown, B. Hesp, and R. E. Giles. 1990. The preclinical pharmacology of ICI 204,219, a peptide leukotriene antagonist. Am. Rev. Respir. Dis. 141:978-987.
16. 4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. 141:988-992.
17. 4-induced bronchoconstriction in subjects with asthma: a concentration effect study of ICI 204,219. Clin. Pharmacol. Ther. 54:430-436.
18. Findlay, S. R., J. M. Barden, C. B. Easley, and M. Glass. 1992. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J. Allergy. Clin. Immunol. 89: 1040-1045.
19. Dahlen, S. E., B. Dahlen, E. Eliasson, H. Johansson, T. Bjoerk, M. Kumlin, K. Boo, J. Whitney, S. Binks, B. King, R. Stark, and O. Zetterstrom. 1991. Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist, ICI 204,219. Adv. Prostaglandin Thromboxane Leukot. Res. 21(A and B):461-464.
20. Taylor, I. K., K. M. O'Shaughnessy, R. W. Fuller, and C. T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
21. 1 antihistamine chlorpheniramine maleate: demonstration of topical effect. Br. J. Dis. Chest 17: 113-121.
22. Schaaf, L., L. Hendeles, and M. Weinberger. 1979. Suppression of seasonal allergic rhinitis symptoms with daily hydroxyzine. J. Allergy Clin. Immunol. 63:129-133.
23. 2 receptors in the human nose: rationale for topical use of combined antihistamine preparations. J. Allergy Clin. Immunol. 70:211-218.
24. Naclerio, R. M., F. M. Baroody, and A. G. Togias. 1991. The role of leukotrienes in allergic rhinitis: a review. Am. Rev. Respir. Dis. 143:S91-S95.
25. 4 and histamine-induced cutaneous vascular reactions in man. J. Allergy Clin. Immunol. 87:93-98.
26. Nathan, R. A., M. Glass, and M. C. Minkwitz. 1994. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 105:483-488.